Literature DB >> 3358404

Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study.

M Palmér1, H O Adami, U B Krusemo, S Ljunghall.   

Abstract

A cohort of 4,163 persons reported to the nationwide Swedish Cancer Registry by reason of hyperparathyroidism was followed for up to 22 completed years (24,593 person-years of observation). The occurrence of malignant disease manifested after parathyroid surgery was investigated through computerized linkage to the entire Cancer Registry. During the entire period, the hyperparathyroidism patients suffered malignant diseases significantly more often than the background population (relative risk (RR) = 1.6, 95% confidence interval (CI) 1.5-1.8). Even if all cases with malignant diseases detected at the same time as hyperparathyroidism or during the first year after parathyroid surgery were eliminated, a significantly increased risk remained for the following years (RR = 1.4, 95% CI 1.2-1.6). A significantly increased relative risk of developing gastrointestinal cancers, endocrine tumors, kidney carcinomas, and mammary carcinomas was found. During the first postoperative year, an increased surveillance of the cohort is likely to have contributed to the increased risk, but detection bias is considered unlikely to be the only explanation for the higher risk during all subsequent years. The findings indicate that hyperparathyroidism either promotes later development of malignant tumors or that this condition and certain malignant diseases have etiologic factors in common.

Entities:  

Mesh:

Year:  1988        PMID: 3358404     DOI: 10.1093/oxfordjournals.aje.a114879

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  25 in total

1.  Coexistent multiple myeloma and MEN type 1.

Authors:  E Romagnoli; S Minisola; V Carnevale; G Spagna; E D'Erasmo; G Mazzuoli
Journal:  Postgrad Med J       Date:  1990-10       Impact factor: 2.401

Review 2.  Parathyroid hormone for the treatment of osteoporosis: a systematic review.

Authors:  Ann Cranney; Alexandra Papaioannou; Nicole Zytaruk; David Hanley; Jonathan Adachi; David Goltzman; Timothy Murray; Anthony Hodsman
Journal:  CMAJ       Date:  2006-07-04       Impact factor: 8.262

3.  Strategies of spinal fusion on osteoporotic spine.

Authors:  Sung Bae Park; Chun Kee Chung
Journal:  J Korean Neurosurg Soc       Date:  2011-06-30

Review 4.  Parathyroid hormone as an anabolic skeletal therapy.

Authors:  Mishaela R Rubin; John P Bilezikian
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Primary hyperparathyroidism in prostate cancer: guilty or not guilty?

Authors:  G Mazziotti; S Frara; A Mosca
Journal:  Endocrine       Date:  2018-05-30       Impact factor: 3.633

6.  Premature death in patients operated on for primary hyperparathyroidism.

Authors:  G Hedbäck; L E Tisell; B A Bengtsson; I Hedman; A Oden
Journal:  World J Surg       Date:  1990 Nov-Dec       Impact factor: 3.352

7.  Primary hyperparathyroidism: epidemiology, diagnosis and clinical picture.

Authors:  S Ljunghall; P Hellman; J Rastad; G Akerström
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

8.  Surgical treatment of primary hyperparathyroidism: an institutional perspective.

Authors:  J A van Heerden; C S Grant
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

Review 9.  Nontraditional manifestations of primary hyperparathyroidism.

Authors:  Marcella Donovan Walker; Mishaela Rubin; Shonni J Silverberg
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

10.  Incidental Finding of Papillary Thyroid Carcinoma in the Patients with Primary Hyperparathyroidism.

Authors:  Pinar Yazici; Mehmet Mihmanli; Emre Bozdag; Nurcihan Aygun; Mehmet Uludag
Journal:  Eurasian J Med       Date:  2015-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.